HIND
Vyome Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.22
−0.45%Year over year
Reported trailing growth
- Revenue
- -98.0%
- EBITDA
- -68.4%
- EBIT
- +45.4%
- EPS
- +78.3%
- Free cash flow
- +106.9%
- Operating cash flow
- +106.9%
Forward estimates
Based on analyst estimates
- Revenue
- -36.6%
- EBITDA
- +41.8%
- EPS
- +96.8%
Three-year CAGR
- Revenue
- -69.5%
- EBITDA
- -55.3%
- EBIT
- +64.5%
- Net income
- -43.9%
- EPS
- +98.6%
- Free cash flow
- +15.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026